Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
PTC Therapeutics, Inc. - Common Stock
(NQ:
PTCT
)
44.23
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about PTC Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Looking Into PTC Therapeutics's Return On Capital Employed
February 22, 2023
Via
Benzinga
Earnings Outlook For PTC Therapeutics
February 20, 2023
Via
Benzinga
Expert Ratings for PTC Therapeutics
December 14, 2022
Via
Benzinga
7 Nasdaq Stocks to Sell Before They Plunge in 2023
December 05, 2022
While loyalty may be a positive trait in most circumstances, when it comes to Nasdaq stocks to sell, you got to look out for number one.
Via
InvestorPlace
PTC Therapeutics's Return On Capital Employed Overview
November 02, 2022
According to Benzinga Pro data, during Q3, PTC Therapeutics (NASDAQ:PTCT) posted sales of $217.13 million. Earnings were up 28.12%, but PTC Therapeutics still reported an overall loss of $109.31...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 28, 2022
Gainers Nuvalent (NASDAQ:NUVL) stock increased by 15.9% to $25.5 during Friday's pre-market session. The company's market cap stands at $1.2 billion.
Via
Benzinga
Reaction Is Overdone For PTC Therapeutics Pausing Huntington Trial Enrollment, Analyst Says
October 19, 2022
Via
Benzinga
PTC Therapeutics Pauses Enrollment In Huntington's Candidate Trial In US
October 19, 2022
Via
Benzinga
What 5 Analyst Ratings Have To Say About PTC Therapeutics
October 17, 2022
Within the last quarter, PTC Therapeutics (NASDAQ:PTCT) has observed the following analyst ratings:
Via
Benzinga
Expert Ratings for PTC Therapeutics
October 17, 2022
Analysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
December 14, 2022
Via
Benzinga
PTC Therapeutics Gets $1B Funding From Blackstone, Shares Fall
October 28, 2022
Via
Benzinga
Analyst Ratings for PTC Therapeutics
October 17, 2022
Within the last quarter, PTC Therapeutics (NASDAQ:PTCT) has observed the following analyst ratings:
Via
Benzinga
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday
October 31, 2022
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 19, 2022
Gainers Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 74.8% to $0.17 during Wednesday's pre-market session. The company's market cap stands at $14.1 million.
Via
Benzinga
Analyst Ratings for PTC Therapeutics
September 09, 2022
Analysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter:
Via
Benzinga
PTC Therapeutics: Q2 Earnings Insights
August 04, 2022
PTC Therapeutics (NASDAQ:PTCT) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Why Edwards Lifesciences Shares Are Trading Lower By Around 17%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
October 28, 2022
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) surged 179% to $3.6301.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 18, 2022
Gainers
Via
Benzinga
Marten Transport, Silvergate Capital And Some Other Big Stocks Moving Lower On Tuesday
October 18, 2022
U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Earnings Scheduled For October 27, 2022
October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Via
Benzinga
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
October 12, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2022
September 12, 2022
Upgrades
Via
Benzinga
Newman Ferrara LLP Announces Corporate Governance Investigations of PTC Therapeutics (PTCT)
September 07, 2022
From
Newman Ferrara LLP
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
Upgrades
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
September 01, 2022
Upgrades
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
July 20, 2022
Via
Benzinga
The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study
July 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
PTC Stock Has Gained 27% This Week Alone, And It's Still Sprinting
June 23, 2022
Shares of PTC stock continued a seven-day run Thursday on promising test results for its Duchenne muscular dystrophy treatment.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.